| William A Cole Jr, MD | |
|
300 North Ave, Battle Creek, MI 49017-3307 | |
| (269) 966-8000 | |
| Not Available |
| Full Name | William A Cole Jr |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 300 North Ave, Battle Creek, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417901299 | NPI | - | NPPES |
| 010275580 | Other | WV | VA MCD |
| 3001521 | Other | WV | WV DWC |
| 001807945 | Other | WV | WV BC/BS |
| 3810004990 | Medicaid | WV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 20318 (West Virginia) | Primary |
| Entity Name | Emergency Professional Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093762353 PECOS PAC ID: 7214832435 Enrollment ID: O20040511000864 |
News Archive
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.
The first National Institutes of Health National Cancer Institute-funded clinical study examining stereotactic body radiotherapy (SBRT) in the treatment of oligometastatic breast, prostate, and non-small cell lung (NSCLC) cancers displayed evidence that SBRT can be safely used to treat patients who have multiple metastases.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that The Journal of Hand Surgery (JHS) has published in its December 2010 online edition pivotal CORD II phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic, conducted by BioSpecifics' strategic partner Auxilium Pharmaceuticals Inc., for the nonsurgical treatment of adult Dupuytren's contracture patients with a palpable cord.
Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications, today announced that it has entered into an exclusive license agreement with affiliates of Fagron NV for the commercialization of OMS103, Omeros' product for arthroscopic surgery.
The three prevalent skin cancers, according to the literature are melanoma, basal cell carcinoma and squamous cell carcinoma.
› Verified 5 days ago
| Entity Name | Ohio Emergency Professionals Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982983425 PECOS PAC ID: 0547433328 Enrollment ID: O20111024000785 |
News Archive
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.
The first National Institutes of Health National Cancer Institute-funded clinical study examining stereotactic body radiotherapy (SBRT) in the treatment of oligometastatic breast, prostate, and non-small cell lung (NSCLC) cancers displayed evidence that SBRT can be safely used to treat patients who have multiple metastases.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that The Journal of Hand Surgery (JHS) has published in its December 2010 online edition pivotal CORD II phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic, conducted by BioSpecifics' strategic partner Auxilium Pharmaceuticals Inc., for the nonsurgical treatment of adult Dupuytren's contracture patients with a palpable cord.
Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications, today announced that it has entered into an exclusive license agreement with affiliates of Fagron NV for the commercialization of OMS103, Omeros' product for arthroscopic surgery.
The three prevalent skin cancers, according to the literature are melanoma, basal cell carcinoma and squamous cell carcinoma.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| William A Cole Jr, MD 4750 Hempstead Station Dr, Kettering, OH 45429-5164 Ph: (800) 875-0136 | William A Cole Jr, MD 300 North Ave, Battle Creek, MI 49017-3307 Ph: (269) 966-8000 |
News Archive
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.
The first National Institutes of Health National Cancer Institute-funded clinical study examining stereotactic body radiotherapy (SBRT) in the treatment of oligometastatic breast, prostate, and non-small cell lung (NSCLC) cancers displayed evidence that SBRT can be safely used to treat patients who have multiple metastases.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that The Journal of Hand Surgery (JHS) has published in its December 2010 online edition pivotal CORD II phase III clinical trial of XIAFLEX (collagenase clostridium histolyticum), a novel, first-in-class biologic, conducted by BioSpecifics' strategic partner Auxilium Pharmaceuticals Inc., for the nonsurgical treatment of adult Dupuytren's contracture patients with a palpable cord.
Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications, today announced that it has entered into an exclusive license agreement with affiliates of Fagron NV for the commercialization of OMS103, Omeros' product for arthroscopic surgery.
The three prevalent skin cancers, according to the literature are melanoma, basal cell carcinoma and squamous cell carcinoma.
› Verified 5 days ago
Dr. Mark Joseph Dzwik, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 Apple Blossom Ln, Battle Creek, MI 49015 Phone: 269-966-4502 | |
Dr. Daniel Patrick Stewart, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5352 Beckley Rd Ste B, Battle Creek, MI 49015 Phone: 269-979-6888 Fax: 269-979-6809 | |
Dr. Paul S Lin, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 North Ave, Battle Creek, MI 49016 Phone: 269-963-5048 | |
Joel Lee Goldberg, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 300 North Avenue, Battle Creek Health Systems Emergency Department, Battle Creek, MI 49017 Phone: 800-726-3627 | |
Jeffrey Richard, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 150 Kendall St S, Battle Creek, MI 49037 Phone: 269-441-4141 Fax: 269-441-4142 | |
David Reis, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 300 North Ave, Battle Creek, MI 49016 Phone: 269-966-8000 |